Melinda Gooderham, MSc, MD, FRCPC

Melinda Gooderham, MSc, MD, FRCPC, emphasized the significance of the study’s results, showcasing stable laboratory parameters over a 12-week trial.

Gooderham reviews key highlights from EADV 2024 on the ADjoin long-term extension trial for patients with moderate to severe AD.

Melinda Gooderham, MSc, MD, FRCPC, discusses potential new biologics for atopic dermatitis that target IL-22, IL-33, OX40, and more.

Melinda Gooderham, MSc, MD, FRCPC, provided insights into the significance of the DELTA 3 extension data presented at AAD 2024.

As deucravacitinib surpasses its 1-year milestone since approval, clinicians continue to monitor its real-world performance among patients.

Gooderham’s sessions covered upcoming AD drug approvals, patient satisfaction and QoL improvement, and RAD 2023 takeaways.